Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 462

1.

The Immune Landscape of Cancer.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I.

Immunity. 2019 Aug 20;51(2):411-412. doi: 10.1016/j.immuni.2019.08.004. No abstract available.

PMID:
31433971
2.

Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer.

Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M 3rd, Hope TA, Carroll PR, Feng FY.

Eur Urol Oncol. 2019 Jan 14. pii: S2588-9311(18)30194-9. doi: 10.1016/j.euo.2018.11.002. [Epub ahead of print]

PMID:
31411984
3.

Guidelines should be assessed based on the underlying evidence.

Carroll PR, Parsons JK.

CMAJ. 2019 Aug 6;191(31):E871. doi: 10.1503/cmaj.72508. No abstract available.

PMID:
31387962
4.

Reply by Authors.

Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC.

J Urol. 2019 Jul 31:10109701JU00005793126115939. doi: 10.1097/01.JU.0000579312.61159.39. [Epub ahead of print] No abstract available.

PMID:
31364932
5.

Hematuria Practice Guidelines That Explicitly Consider Harms and Costs.

Bauer SR, Carroll PR, Grady D.

JAMA Intern Med. 2019 Jul 29. doi: 10.1001/jamainternmed.2019.2269. [Epub ahead of print] No abstract available.

PMID:
31355847
6.

Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry.

Jeong CW, Cowan JE, Broering JM, Ten Ham RMT, Wilson LS, Carroll PR, Cooperberg MR.

Eur Urol. 2019 Jul 22. pii: S0302-2838(19)30536-6. doi: 10.1016/j.eururo.2019.07.012. [Epub ahead of print]

PMID:
31345635
7.

Automating the Capture of Structured Pathology Data for Prostate Cancer Clinical Care and Research.

Odisho AY, Bridge M, Webb M, Ameli N, Eapen RS, Stauf F, Cowan JE, Washington SL 3rd, Herlemann A, Carroll PR, Cooperberg MR.

JCO Clin Cancer Inform. 2019 Jul;3:1-8. doi: 10.1200/CCI.18.00084.

8.

A Mobile Health Intervention for Prostate Biopsy Patients Reduces Appointment Cancellations: Cohort Study.

Balakrishnan AS, Nguyen HG, Shinohara K, Au Yeung R, Carroll PR, Odisho AY.

J Med Internet Res. 2019 Jun 2;21(6):e14094. doi: 10.2196/14094.

9.

Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.

Masic S, Cowan JE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR.

Eur Urol Oncol. 2018 Oct;1(5):386-394. doi: 10.1016/j.euo.2018.04.018. Epub 2018 May 24.

PMID:
31158077
10.

Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor.

Balakrishnan AS, Zhao S, Cowan JE, Broering JM, Cooperberg MR, Carroll PR.

Urology. 2019 May 28. pii: S0090-4295(19)30494-7. doi: 10.1016/j.urology.2019.05.018. [Epub ahead of print]

PMID:
31150694
11.

SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.

Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC.

J Urol. 2019 May 30:101097JU0000000000000357. doi: 10.1097/JU.0000000000000357. [Epub ahead of print]

PMID:
31144591
12.

Detection of clinically signifi cant prostate cancer with PIRADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions.

Westphalen AC, Fazel F, Nguyen H, Cabarrus M, Hanley-Knutson K, Shinohara K, Carroll PR.

Int Braz J Urol. 2019 Jul-Aug;45(4):713-723. doi: 10.1590/S1677-5538.IBJU.2018.0768.

13.

The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.

Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF.

Eur Urol. 2019 Sep;76(3):268-272. doi: 10.1016/j.eururo.2019.05.013. Epub 2019 May 23.

PMID:
31128968
14.

Trends in Complementary and Alternative Medicine Use among Patients with Prostate Cancer.

Zuniga KB, Zhao S, Kenfield SA, Cedars B, Cowan JE, Van Blarigan EL, Broering JM, Carroll PR, Chan JM.

J Urol. 2019 May 15:101097JU0000000000000336. doi: 10.1097/JU.0000000000000336. [Epub ahead of print]

PMID:
31091175
15.

Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer.

Lawhn-Heath C, Flavell RR, Behr SC, Yohannan T, Greene KL, Feng F, Carroll PR, Hope TA.

AJR Am J Roentgenol. 2019 Aug;213(2):266-274. doi: 10.2214/AJR.18.20699. Epub 2019 Apr 30.

PMID:
31039025
16.

A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology for Men on Active Surveillance.

Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR.

J Urol. 2019 Apr 26:101097JU0000000000000290. doi: 10.1097/JU.0000000000000290. [Epub ahead of print]

PMID:
31026214
17.

Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance of Early Stage Prostate Cancer.

Cedars BE, Washington SL 3rd, Cowan JE, Leapman M, Tenggara I, Chan JM, Cooperberg MR, Carroll PR.

J Urol. 2019 Apr 8:101097JU0000000000000271. doi: 10.1097/JU.0000000000000271. [Epub ahead of print]

PMID:
30958742
18.

Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.

Balakrishnan AS, Cowan JE, Cooperberg MR, Shinohara K, Nguyen HG, Carroll PR.

J Urol. 2019 Sep;202(3):506-510. doi: 10.1097/JU.0000000000000247. Epub 2019 Aug 8.

PMID:
30958738
19.

Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy.

Boreta L, Gadzinski AJ, Wu SY, Xu M, Greene K, Quanstrom K, Nguyen HG, Carroll PR, Hope TA, Feng FY.

Urology. 2019 Jul;129:165-171. doi: 10.1016/j.urology.2018.12.055. Epub 2019 Mar 27.

PMID:
30928607
20.

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA.

JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096.

Supplemental Content

Loading ...
Support Center